Solomon Philip, Ng Chew Lip, Kerzner Jaimie, Rival Richard
Department of Otolaryngology-Head and Neck Surgery, University of Toronto Faculty of Medicine, Toronto, Ontario, Canada.
Plast Surg (Oakv). 2021 May;29(2):98-102. doi: 10.1177/2292550320933675. Epub 2020 Jun 30.
Bellafill (Suneva Medical Inc) is a semipermanent injectable soft tissue filler composed of smooth and uniform polymethylmetacrylate (PMMA) microspheres suspended in a bovine collagen gel. It is a third generation PMMA filler, with more uniform shapes and sizes of the PMMA microspheres, which has been purported to decrease the incidence of granuloma formation.
We performed a retrospective review of our clinical experience from 2014 to 2017 with Bellafill as a soft tissue injectable filler in the following clinical scenarios: deep nasolabial folds, depressed facial acne scars, malar volume loss, temporal wasting, tear trough deformity, chin augmentation, angle of jaw augmentation, and lip augmentation. The primary outcome is the rate of adverse events, and the secondary outcome is subjective patient satisfaction.
From 2014 to 2017, 842 syringes of Bellafill were administered to 212 patients, for a total of 417 procedures. Of the 417 procedures, 96 (23.0%) were for acne scars, 82 (19.7%) malar volume restorations, 65 (15.6%) nasolabial fold augmentations, 45 (10.8%) chin augmentations, 42 (10.1%) tear trough volume restorations, 28 (6.7%) temple volume restorations, 25 (6.0%) rhinoplasty touch-ups for small areas of nasal depression, 22 (5.3%) lip augmentations, and 12 (2.9%) jaw angle augmentations were performed. A range of 1 to 12 syringes were injected into each patient, over 1 to 3 sessions; 6 cases of adverse events occurred (1.4%). There were 4 cases of solitary nodules in the injection site, 1 case of lower eyelid oedema which persisted for 3 months and 1 case of lower lip oedema which resolved within hours. Patient satisfaction rates ranged from 83.3% for angle of jaw augmentation to 99.0% for improvement of acne scars.
Bellafill is a safe and effective option for a semipermanent soft tissue filler, with high patient satisfaction and a good safety profile.
贝拉菲尔（Suneva Medical Inc公司）是一种半永久性可注射软组织填充剂，由悬浮于牛胶原蛋白凝胶中的光滑且均匀的聚甲基丙烯酸甲酯（PMMA）微球组成。它是第三代PMMA填充剂，PMMA微球的形状和尺寸更加均匀，据称可降低肉芽肿形成的发生率。
我们对2014年至2017年期间在以下临床情况中使用贝拉菲尔作为软组织可注射填充剂的临床经验进行了回顾性研究：深层鼻唇沟、面部痤疮凹陷性瘢痕、颧骨容积减少、颞部凹陷、泪沟畸形、隆颏、下颌角增大及隆唇。主要结局是不良事件发生率，次要结局是患者主观满意度。
2014年至2017年，共向212例患者注射了842支贝拉菲尔注射器，总计进行了417次手术。在这417次手术中，96次（23.0%）用于痤疮瘢痕，82次（19.7%）用于颧骨容积恢复，65次（15.6%）用于鼻唇沟填充，45次（10.8%）用于隆颏，42次（10.1%）用于泪沟容积恢复，28次（6.7%）用于颞部容积恢复，25次（6.0%）用于小面积鼻凹陷的隆鼻修复，22次（5.3%）用于隆唇，12次（2.9%）用于下颌角增大。每位患者在1至3次疗程中注射了1至12支注射器；发生了6例不良事件（1.4%）。注射部位出现4例孤立性结节，1例下眼睑水肿持续3个月，1例下唇水肿在数小时内消退。患者满意度从下颌角增大的83.3%到痤疮瘢痕改善的99.0%不等。
贝拉菲尔作为一种半永久性软组织填充剂是一种安全有效的选择，患者满意度高且安全性良好。
